SMi discloses £6 million seed funding round, bolsters team with new C-suite hire
Summary
SMis approach will allow diagnostic testing centres to rapidly detect biomarkers and enable earlier patient diagnosis for a range of life-threatening diseases. Risley, an experienced senior manager, has a track record of developing and delivering complex, regulated in vitro diagnostic (IVD) products. Complementing SMis existing comprehensive research expertise, Risleys leadership and experience will take key elements of the new platform from concept to commercialization conforming to regulatory standards.Weve proved the success of our new platform in both respiratory diseases and cancer biomarker diagnosis, but were only just scratching the surface of what is possible using our single molecule imaging technology, says Dr Andrew Thompson, Chief Executive Officer (CEO) at SMi. With the significant investment weve received and the appointment of Michael as CDO, were building a strong foundation for us to continue developing our products and accelerate their implementation for a vast range of applications, from disease diagnosis to drug and vaccine discovery. Its technology will have a significant impact across the life science industry, giving deeper insights to the most complex questions troubling researchers and clinicians.